CR20200123A - Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre - Google Patents

Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre

Info

Publication number
CR20200123A
CR20200123A CR20200123A CR20200123A CR20200123A CR 20200123 A CR20200123 A CR 20200123A CR 20200123 A CR20200123 A CR 20200123A CR 20200123 A CR20200123 A CR 20200123A CR 20200123 A CR20200123 A CR 20200123A
Authority
CR
Costa Rica
Prior art keywords
pyruvate kinase
blood disorders
treating blood
kinase activators
activators
Prior art date
Application number
CR20200123A
Other languages
English (en)
Inventor
Jingjing Ji
Zhihua Sui
Tao Liu
Dawei Cui
Zhenwei Cai
Giovanni Cianchetta
Anil Kumar Padyana
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CR20200123A publication Critical patent/CR20200123A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos que activan la piruvato quinasa, composiciones farmacéuticas y métodos para usarlos. Estos compuestos están representadospor la fórmula (I): donde R1, R2, Ra, Rb, Rj, Rk y Q son como se los define en la presente.
CR20200123A 2017-08-15 2018-08-15 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre CR20200123A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Publications (1)

Publication Number Publication Date
CR20200123A true CR20200123A (es) 2020-06-29

Family

ID=63524352

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200123A CR20200123A (es) 2017-08-15 2018-08-15 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre

Country Status (32)

Country Link
US (7) US11364240B2 (es)
EP (4) EP4026838A1 (es)
JP (4) JP7275107B2 (es)
KR (3) KR102642408B1 (es)
CN (3) CN111032046B (es)
AU (3) AU2018316588B2 (es)
BR (2) BR112020003262A2 (es)
CA (2) CA3071993A1 (es)
CL (1) CL2020000375A1 (es)
CO (2) CO2020002961A2 (es)
CR (1) CR20200123A (es)
CY (1) CY1124953T1 (es)
DK (2) DK3668513T3 (es)
EC (1) ECSP20018487A (es)
ES (3) ES2966825T3 (es)
FI (1) FI3668512T3 (es)
HR (2) HRP20230452T1 (es)
HU (2) HUE061910T2 (es)
IL (3) IL272599B (es)
LT (2) LT3668512T (es)
MD (1) MD3668513T2 (es)
MX (2) MX2020001832A (es)
PE (1) PE20200724A1 (es)
PH (1) PH12020500343A1 (es)
PL (2) PL3668513T3 (es)
PT (2) PT3668513T (es)
RS (2) RS64221B1 (es)
SG (2) SG11202001353PA (es)
SI (2) SI3668513T1 (es)
TW (3) TWI796353B (es)
UA (1) UA126292C2 (es)
WO (3) WO2019035863A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014032A (es) 2017-03-20 2019-08-21 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato cinasa (pkr).
CN111032046B (zh) 2017-08-15 2023-09-26 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
US20220127267A1 (en) * 2019-02-13 2022-04-28 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
JPWO2020262419A1 (es) * 2019-06-26 2020-12-30
AU2021311597A1 (en) * 2020-07-21 2023-02-02 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
CA3231728A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
AU2022390088A1 (en) * 2021-11-16 2024-05-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
KR20020091829A (ko) 1999-07-30 2002-12-06 애보트 게엠베하 운트 콤파니 카게 2-피라졸린-5-온
EP1214296B1 (en) 1999-09-04 2004-03-24 AstraZeneca AB Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU2009274027A1 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010025202A1 (en) * 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
CA3041868C (en) 2008-10-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase
CA2758071C (en) * 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
IN2012DN00471A (es) 2009-06-29 2015-06-05 Agios Pharmaceuticals Inc
EP2563761A1 (en) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
EP2649053B1 (en) 2010-12-06 2015-11-04 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
US9388164B2 (en) 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
RU2675656C2 (ru) * 2011-05-03 2018-12-21 Аджиос Фармасьютикалз, Инк. Способы применения активаторов пируваткиназы
AU2012250690B2 (en) 2011-05-03 2017-06-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
US8969363B2 (en) * 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
EP2917207A1 (en) * 2012-11-08 2015-09-16 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions and their use as pkm2 modulators
EP2951181A1 (en) * 2013-01-30 2015-12-09 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
MX365950B (es) * 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TWI789401B (zh) 2017-07-07 2023-01-11 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
AR112690A1 (es) 2017-08-15 2019-11-27 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CN111032046B (zh) 2017-08-15 2023-09-26 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途
SG10202106345VA (en) 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
US20220127267A1 (en) * 2019-02-13 2022-04-28 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Also Published As

Publication number Publication date
WO2019035864A1 (en) 2019-02-21
ES2966825T3 (es) 2024-04-24
CN111032045A (zh) 2020-04-17
CA3071993A1 (en) 2019-02-21
HRP20230452T1 (hr) 2023-07-21
JP2023027276A (ja) 2023-03-01
MX2020001833A (es) 2020-07-22
WO2019035864A8 (en) 2019-03-28
RU2020110573A3 (es) 2021-12-24
WO2019035863A8 (en) 2019-03-28
RS62871B1 (sr) 2022-02-28
IL272599A (en) 2020-03-31
PL3668513T3 (pl) 2022-03-21
CN111032046B (zh) 2023-09-26
UA126292C2 (uk) 2022-09-14
EP3668513B1 (en) 2021-11-10
IL272597A (en) 2020-03-31
SI3668513T1 (sl) 2022-04-29
KR20200054200A (ko) 2020-05-19
PL3668512T3 (pl) 2023-06-19
IL272599B (en) 2022-08-01
TWI790271B (zh) 2023-01-21
BR112020003262A2 (pt) 2020-09-01
AU2018316588B2 (en) 2023-02-02
PE20200724A1 (es) 2020-07-21
EP4026838A1 (en) 2022-07-13
AU2018316587A1 (en) 2020-02-20
ECSP20018487A (es) 2020-05-29
WO2019035865A8 (en) 2019-03-28
JP7301040B2 (ja) 2023-06-30
CN117186119A (zh) 2023-12-08
CY1124953T1 (el) 2023-01-05
CO2020002961A2 (es) 2020-04-13
AU2018316587B2 (en) 2023-05-11
JP2023052478A (ja) 2023-04-11
BR112020003254A2 (pt) 2020-10-27
HRP20220039T1 (hr) 2022-04-15
RS64221B1 (sr) 2023-06-30
SG11202001353PA (en) 2020-03-30
EP3668512B1 (en) 2023-02-15
IL272597B (en) 2022-06-01
US20230226055A1 (en) 2023-07-20
IL292530B2 (en) 2023-06-01
JP2020531443A (ja) 2020-11-05
JP7275107B2 (ja) 2023-05-17
IL292530A (en) 2022-06-01
US11872225B2 (en) 2024-01-16
EP3668881B1 (en) 2023-10-04
SG11202001262QA (en) 2020-03-30
US11364240B2 (en) 2022-06-21
CL2020000375A1 (es) 2020-12-11
AU2023202772A1 (en) 2023-05-18
TW202323258A (zh) 2023-06-16
WO2019035865A1 (en) 2019-02-21
MD3668513T2 (ro) 2022-04-30
DK3668512T3 (da) 2023-05-22
HUE057178T2 (hu) 2022-04-28
EP3668513A1 (en) 2020-06-24
US20220233541A1 (en) 2022-07-28
CO2020002959A2 (es) 2020-04-13
AU2018316588A1 (en) 2020-02-20
KR20200054199A (ko) 2020-05-19
HUE061910T2 (hu) 2023-08-28
US11590132B2 (en) 2023-02-28
US11957680B2 (en) 2024-04-16
SI3668512T1 (sl) 2023-06-30
WO2019035863A1 (en) 2019-02-21
RU2020110573A (ru) 2021-09-16
TWI796353B (zh) 2023-03-21
MX2020001832A (es) 2020-07-22
CN111032045B (zh) 2023-08-15
US20210130371A1 (en) 2021-05-06
ES2905100T3 (es) 2022-04-07
KR102642408B1 (ko) 2024-02-28
EP3668881A1 (en) 2020-06-24
JP2020531432A (ja) 2020-11-05
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
US20220395503A1 (en) 2022-12-15
FI3668512T3 (fi) 2023-05-12
ES2944545T3 (es) 2023-06-22
CN111032046A (zh) 2020-04-17
US20210077490A1 (en) 2021-03-18
CA3072455A1 (en) 2019-02-21
US11040036B2 (en) 2021-06-22
US20200206225A1 (en) 2020-07-02
US11464775B2 (en) 2022-10-11
US20200207785A1 (en) 2020-07-02
KR20230127364A (ko) 2023-08-31
TW201920203A (zh) 2019-06-01
AU2023202772B2 (en) 2024-05-16
LT3668513T (lt) 2022-03-25
DK3668513T3 (da) 2022-01-10
PT3668512T (pt) 2023-05-22
PH12020500343A1 (en) 2021-02-08
TW201919631A (zh) 2019-06-01
EP3668512A1 (en) 2020-06-24
LT3668512T (lt) 2023-06-12

Similar Documents

Publication Publication Date Title
PH12020500343A1 (en) Pyruvate kinase activators for use in treating blood disorders
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MY190548A (en) Tyrosine kinase inhibitors
PH12016501440A1 (en) Novel heterocyclic compounds
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
NZ726608A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726360A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
TW201613864A (en) Novel compounds
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2020010577A (es) Derivados de morfolina como inhibidores de vps34.
EA202090507A1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови